Effect of in-hospital evolocumab therapy on lipoprotein(a) in patients with acute myocardial infarction: a retrospective cohort study and a propensity score matching analysis

Elevated lipoprotein(a) is associated with an increased risk of atherosclerotic cardiovascular disease. Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, has been shown to reduce lipoprotein(a). However, the effect of evolocumab on lipoprotein(a) in patients with acute myocardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ge, Zheng, Tao, Lan, Beidi, Hui, Weiying, Chen, Shi, Yuan, Zuyi, Wu, Yue, Chiang, John Y. L., Chen, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179980/
https://www.ncbi.nlm.nih.gov/pubmed/37187811
http://dx.doi.org/10.1097/CP9.0000000000000036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179980/
https://www.ncbi.nlm.nih.gov/pubmed/37187811
http://dx.doi.org/10.1097/CP9.0000000000000036

Ejemplares similares